MYR 0.25
(-3.92%)
Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 35.6 Million | 27.52 Million | 20.51 Million | 15.36 Million | 7.67 Million |
Cost of Revenue | 17.05 Million | 15.79 Million | 9.23 Million | 6.94 Million | 3.84 Million |
Gross Profit | 18.54 Million | 11.73 Million | 11.28 Million | 8.42 Million | 3.82 Million |
Operating Expenses | 7.25 Million | 5.43 Million | 3.17 Million | 2.86 Million | 2.77 Million |
Selling, General and Administrative Expenses | 8.17 Million | 5.43 Million | 3.18 Million | 2.95 Million | 2.77 Million |
Research and Development Expenses | - | - | - | - | - |
Other Expenses | -915.73 Thousand | - | - | - | - |
Cost and Expenses | 24.31 Million | 21.23 Million | 12.4 Million | 9.81 Million | 6.62 Million |
Operating Income | 11.28 Million | 8.09 Million | 8.2 Million | 5.59 Million | 1.07 Million |
Interest Expense | 402.98 Thousand | 196.05 Thousand | 196.07 Thousand | 32 Thousand | 6179.00 |
Income Tax Expense | 96.44 Thousand | 95.81 Thousand | -169.98 Thousand | - | -302.49 Thousand |
Earnings before Tax | 10.88 Million | 7.9 Million | 8 Million | 5.56 Million | 1.06 Million |
Net Income | 10.78 Million | 7.8 Million | 8.17 Million | 5.56 Million | 1.36 Million |
Earnings Per Share Basic | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 |
Earnings Per Share Diluted | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 |
Weighted Average Shares Outstanding | 577.56 Million | 577.5 Million | 577.5 Million | 577.5 Million | 577.5 Million |
Weighted Average Shares Outstanding (Diluted) | 577.53 Million | 577.5 Million | 577.5 Million | 577.5 Million | 577.5 Million |
Gross Margin | 0.52 | 0.43 | 0.55 | 0.55 | 0.50 |
EBIT Margin | 0.35 | 0.31 | 0.41 | 0.38 | 0.16 |
Profit Margin | 0.30 | 0.28 | 0.40 | 0.36 | 0.18 |
EBITDA | 12.6 Million | 8.5 Million | 8.55 Million | 5.88 Million | 1.26 Million |
Earnings Before Tax Margin | 0.32 | 0.29 | 0.40 | 0.36 | 0.14 |
Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
---|---|---|---|---|---|---|
Revenue | 4.02 Million | 5.8 Million | 5.61 Million | 4.7 Million | 35.6 Million | 10.91 Million |
Cost of Revenue | 4.68 Million | 3.69 Million | 3.8 Million | 3.01 Million | 17.05 Million | 5.59 Million |
Gross Profit | -661 Thousand | 2.11 Million | 1.81 Million | 1.68 Million | 18.54 Million | 5.31 Million |
Operating Expenses | 1.71 Million | 1.82 Million | 1.69 Million | 1.61 Million | 7.65 Million | 2.18 Million |
Selling, General and Administrative Expenses | 1.72 Million | 1.87 Million | 1.7 Million | 2.02 Million | - | 2.23 Million |
Research and Development Expenses | - | - | - | - | - | - |
Other Expenses | -17 Thousand | - | - | - | - | - |
Cost and Expenses | 6.39 Million | 5.52 Million | 5.5 Million | 4.62 Million | 24.7 Million | 7.78 Million |
Operating Income | -2.37 Million | 289 Thousand | 117 Thousand | -447.17 Thousand | 10.37 Million | 3.13 Million |
Interest Expense | 150 Thousand | 139 Thousand | 103 Thousand | - | - | 111 Thousand |
Income Tax Expense | 183 Thousand | 102 Thousand | 151 Thousand | 96.44 Thousand | 96.44 Thousand | 128 Thousand |
Earnings before Tax | -2.34 Million | 252 Thousand | 165 Thousand | 73.57 Thousand | 10.88 Million | 3.14 Million |
Net Income | -2.34 Million | 252 Thousand | 165 Thousand | -22.87 Thousand | 10.78 Million | 3.14 Million |
Earnings Per Share Basic | -0.00 | 0.00 | 0.00 | - | - | 0.01 |
Earnings Per Share Diluted | -0.00 | 0.00 | 0.00 | - | - | 0.01 |
Weighted Average Shares Outstanding | 579.04 Million | 579.04 Million | 579.04 Million | 586.43 Million | 577.56 Million | 577.5 Million |
Weighted Average Shares Outstanding (Diluted) | 579.04 Million | 579.04 Million | 579.04 Million | 577.53 Million | 577.53 Million | 577.5 Million |
Gross Margin | -0.16 | 0.36 | 0.32 | 0.36 | 0.52 | 0.49 |
EBIT Margin | -0.43 | 0.15 | 0.13 | -0.04 | - | 0.34 |
Profit Margin | -0.58 | 0.04 | 0.03 | -0.00 | 0.30 | 0.29 |
EBITDA | -1.72 Million | 848 Thousand | 719 Thousand | -172.46 Thousand | - | 3.74 Million |
Earnings Before Tax Margin | -0.59 | 0.05 | 0.02 | -0.10 | 0.29 | 0.29 |
CARL-A
JPAVF
FFARMS
RDC
PSG
TCNAF